This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Beta blockers and hyperlipidaemia

Authoring team

  • tend to result in an increase in triglyceride level (via an increase in VLDL) and a reduction in HDL
    • increase in VLDL appears to be result of reduced clearance of triglyceride-rich lipoproteins (possibly via direct effect on lipoprotein lipase or perhaps because of diversion of blood flow from sites rich in lipoprotein lipase e.g. muscle vascular bed)
  • do not appear to affect total cholesterol or LDL cholesterol
  • if a patient has a predisposition to hypertriglyceridaemia then beta blocker effect can be marked

Labetalol, which posseses both alpha and beta-blocking activity, is reported to have little effect on serum lipids. Also beta-blockers with intrinsic sympathomimetic activity e.g. acebutolol and oxprenolol, are reported to have little effect on serum lipids.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.